Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Lidocaine for Preventing Oxaliplatin-induced Peripheral Neuropathy
NCT03254394Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Lidocaine Hydrochloride Injection, without epinephrine in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Washington University School of Medicine. Started Sep 2017; status: completed.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT03254394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254394.